Grants and Contributions:
Title:
Medical applications of cannabis and fungal extracts
Agreement Number:
981927
Agreement Value:
$463,000.00
Agreement Date:
Nov 1, 2021 - Feb 29, 2024
Description:
Development of novel botanical and fungal extracts for treatment inflammation in various human tissues. Using a combination of in vitro and in vivo assays, including single cell cultures, 3D tissues and mice/rat models, Pathway will develop formulations for treatment and prevention of inflammation-related conditions.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Calgary, Alberta, CA T3H 4Z2
Reference Number:
172-2021-2022-Q3-981927
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
725412480
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 152 days. The total amended value is 85,000 dollars.
Amendment Date
Sep 5, 2023
Recipient's Legal Name:
Pathway Rx Inc.
Federal Riding Name:
Calgary Signal Hill
Federal Riding Number:
48012
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
32541
Amendments: